Brain tumor clues: can MRI and a protein guide treatment?
NCT ID NCT06090903
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at whether MRI scans and a protein called decorin can help identify which glioblastoma patients might benefit from a drug called bevacizumab. Researchers will collect tissue samples from 50 patients during surgery and compare them with MRI images. The goal is to find imaging markers that predict treatment response, not to test a new therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which glioblastoma patients will respond to bevacizumab, potentially personalizing treatment and saving costs.
- What could go wrong
- This is an early observational study with only 50 participants, so results may not apply to all patients. It does not test a new treatment directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?